Equities analysts forecast that Dova Pharmaceuticals Inc (NASDAQ:DOVA) will announce ($0.46) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Dova Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.42) and the lowest estimate coming in at ($0.48). The business is scheduled to announce its next earnings results on Thursday, May 17th.
According to Zacks, analysts expect that Dova Pharmaceuticals will report full-year earnings of ($1.45) per share for the current fiscal year, with EPS estimates ranging from ($1.81) to ($0.85). For the next fiscal year, analysts anticipate that the business will report earnings of $0.47 per share, with EPS estimates ranging from ($1.65) to $3.64. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that follow Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its earnings results on Thursday, February 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.36). During the same period in the prior year, the business earned ($0.44) earnings per share.
Several large investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC raised its stake in shares of Dova Pharmaceuticals by 3.1% during the 4th quarter. Perceptive Advisors LLC now owns 1,809,015 shares of the company’s stock valued at $52,099,000 after purchasing an additional 55,000 shares during the period. BlackRock Inc. raised its stake in shares of Dova Pharmaceuticals by 152.4% during the 4th quarter. BlackRock Inc. now owns 576,799 shares of the company’s stock valued at $16,611,000 after purchasing an additional 348,290 shares during the period. Nexthera Capital LP raised its stake in shares of Dova Pharmaceuticals by 3.4% during the 4th quarter. Nexthera Capital LP now owns 453,032 shares of the company’s stock valued at $13,047,000 after purchasing an additional 14,913 shares during the period. Wells Fargo & Company MN raised its stake in shares of Dova Pharmaceuticals by 62.1% during the 3rd quarter. Wells Fargo & Company MN now owns 324,287 shares of the company’s stock valued at $7,874,000 after purchasing an additional 124,287 shares during the period. Finally, Pier Capital LLC raised its stake in shares of Dova Pharmaceuticals by 37.2% during the 4th quarter. Pier Capital LLC now owns 160,123 shares of the company’s stock valued at $4,612,000 after purchasing an additional 43,408 shares during the period. Institutional investors own 26.05% of the company’s stock.
Shares of DOVA traded up $0.83 during mid-day trading on Friday, hitting $28.31. The stock had a trading volume of 439,646 shares, compared to its average volume of 149,938. The firm has a market cap of $796.98 and a PE ratio of -20.22. Dova Pharmaceuticals has a 52 week low of $16.98 and a 52 week high of $37.00.
ILLEGAL ACTIVITY WARNING: “Dova Pharmaceuticals Inc (DOVA) Expected to Announce Earnings of -$0.46 Per Share” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3341743/dova-pharmaceuticals-inc-dova-expected-to-announce-earnings-of-0-46-per-share.html.
About Dova Pharmaceuticals
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.